Abstract
Rhabdomyosarcoma (RMS) is one of the most common extracranial solid tumours in children. Embryonal and alveolar subtypes of RMS present completely different genetic abnormalities. Embryonal RMS (eRMS) is characterised by loss of heterozygosity on the short arm of chromosome 11 (11p15.5), suggesting inactivation of a tumour-suppressor gene. In contrast, the majority (80–85%) of the alveolar RMS (aRMS) have the reciprocal chromosomal translocations ‘t(2;13)(q35;q14) or t(1;13)(p36;q14). t(2;13) appears in approximately 70% of patients with the alveolar subtype. The molecular counterpart of this translocation consists of the generation of a chimeric fusion gene involving the /PAX3/ gene located in chromosome 2 and a member of the fork-head family, /FOXO1/ (formerly /FKHR/), located in chromosome 13. A less frequent variant translocation t(1;13) involves another PAX family gene, /PAX7/, located in chromosome 1 and /FOXO1/ and is present in 10–15% of cases of the alveolar subtype in RMS. Recently, many studies focused on cancer have demonstrated the great potential of the genomic approach based on tumour expression profiles. These technologies permit the identification of new regulatory pathways. Molecular detection of minimal disease by a sensitive method could contribute to better treatment stratification in these patients. In RMS, the advances in the knowledge of the biological characteristics of the tumour are slowly translated into the clinical management of children with this tumour.
Similar content being viewed by others
References
IARC (1998) International incidence of childhood cancer, 1998 (IICC-2), Vol. II. IARC Scientific Publication No. 144
Meyer WH, Spunt SL (2004) Soft tissue sarcomas of childhood. Cancer Treat Rev 30:269–280
Pappo AS, Shapiro DN, Crist WM, Maurer HM (1995) Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13:2123–2139
Crist WM, Anderson JR, Meza JL et al (2001) Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19:3091–3102
Raney RB, Anderson JR, Barr FG et al (2001) Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V. Am J Pediatr Hematol Oncol 23:215–220
Newton WA Jr, Gehan EA, Webber BL et al (1995) Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification — an Intergroup Rhabdomyosarcoma Study. Cancer 76:1073–1085
Scrable H, Witte D, Shimada H et al (1989) Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1:23–35
Loh EWJ, Scrable HJ, Livanos E et al. Human chromosome 11 contains two different growth suppresser genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A 89:1755–1759
Bridge JA, Liu J, Weibolt V et al (2000) Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization: an Intergroup Rhabdomyosarcoma Study. Genes Chromosome Cancer 27: 337–344
Barr FG (1997) Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 19:483–491
Barr FG (2001) Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20:5736–5746
Galili N, Davis RJ, Fredericks WJ et al (1993) Fusion of a fork head domain gene to PAX 3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5:230–235
Davis RJ, D’Cruz CM, Lowell MA et al (1994) Fusion of PAX7 to the FKHR by the variant t(1;13) (p36;q14)translocation in alveolar rhabdomyosarcomas. Cancer Res 54:2869–2872
Bennicelli JL, Fredericks WJ, Wilson RB et al (1995) Wild-type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11: 119–130
Ludolph DC, Konieczny SF (1995) Transcription factor families: muscling in on the myogenic program. FASEB J 9:1595–1604
Scheidler S, Fredericks WJ, Rauscher FJ III (1996) The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci U S A 93:9805–9809
Bernasconi M, Remppis A, Fredericks WJ et al (1996) Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A 93: 13164–13169
Anderson J, Gordon A, Pritchard-Jones K et al (1999) Genes, chromosomes and rhabdomyosarcoma. Genes Chromosome Cancer 26:275–285
Sorensen PHB, Lynch JC, Qualman SJ et al (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol 20:2672–2679
Driman D, Thorner PS, Greenberg ML et al (1994) MYCN gene amplification in rhabdomyosarcoma. Cancer 15:2231–2237
Forus A, Florenes VA, Maelandsmo GM et al (1993) Mapping of amplification units in the q13–14 region of chromosome 12 in human sarcomas: some amplicons do not include MDM2. Cell Growth Differ 4:1065–1070
Visser M, Sijmons C, Bras J et al (1997) Allelotype of pediatric rhabdomyosarcoma. Oncogene 15:1309–1314
Skubitz KM, Skubitz AP (2004) Characterization of sarcomas by means of gene expression. J Lab Clin Med 144:78–91
Baird K, Davis S, Antonescu CR et al (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65:9226–9235
West RB, van de Rijn M (2006) The role of microarray technologies in the study of soft tissue tumours. Histopathology 48:22–31
Khan J, Wie JS, Ringner M et al (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7:673–679
Baer C, Nees M, Breit S et al (2004) Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing’s sarcoma. Int J Cancer 110:687–694
Schaaf GJ, Ruijter JM, van Ruissen F et al (2005) Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. FASEB J 19:404–406
Romualdi C, De Pitta C, Tombolan L et al (2006) Defining the gene expression signature of rhabdomyosarcoma by meta-analysis. BMC Genomics 7:287
Athale U, Shurtleff S, Jenkins J et al (2001) Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 23:99–104
Kelly KM, Womer RB, Barr FG (1996) Minimal disease detection in patients with alveolar rhabdomyosarcoma using a reverse transcriptase-polymerase chain reaction method. Cancer 78:1320–1327
Frascella E, Rosolen A (1998) Detection of the MyoD1 transcript in rhabdomyosarcoma cell lines and tumor samples by reverse transcription polymerase chain reaction. Am J Pathol 152:577–583
Gattenloehner S, Dockhorn-Dworniczak B, Leuschner I et al (1999) A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas. J Mol Diagn 1:23–31
Gallego S, Llort A, Roma J (2006) Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay. J Cancer Res Clin Oncol 132:356–362
Sartori F, Alaggio R, Zanazzo G et al (2006) Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers. Cancer 106:1766–1775
MacKeigan JP, Murphy LO, Blenis J (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7:591–600
McDowell HP, Meco D, Riccardi A et al (2006) Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. Int J Cancer 120:1141–1149
Petricoin EF, Espina V, Araujo RP et al (2007) Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 67:3431–3440
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by an unrestricted educational grant from Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Gallego Melcón, S., Sánchez de Toledo Codina, J. Molecular biology of rhabdomyosarcoma. Clin Transl Oncol 9, 415–419 (2007). https://doi.org/10.1007/s12094-007-0079-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-007-0079-3